 In Part II, patients will be randomized 1:1 to two treatment groups: Arm A Tarceva MTD established in Part I and Arm B 150 mg Tarceva daily. Patients in both arms will be treated for two weeks and then have pharmacokinetic samples collected on day 14. Part II is open as of Nov-2006. 